


ONCOLOGY NETWORK

Medicon Valley Alliance



PERSONALISED MEDICINE FOR CANCER PATIENTS
8th of December 2020

In Collaboration with:



LUND UNIVERSITY



UNIVERSITY OF
COPENHAGEN

Sponsored by:

HØIBERG
European Patent Attorneys

medicon valley **alliance**

PART OF

**GREATERT
COPENHAGEN**

Welcome to the MVA Oncology Network

House-keeping rules

- You are automatically muted
- Use the Chat for technical questions
- Use the Q&A for questions to the speakers
- You will receive a link to the presentations after the event

Please note that this event will be recorded.

THE MVA NETWORKS



Medicon Valley Alliance Oncology Network is a network initiated by Danish and Swedish business and academia within the field of oncology



MVA R&D Network focus on best practice and current challenges for industry-academia collaboration and the commercialization of R&D in the Medicon Valley region



Medicon Valley Medtech Network gather the region's Medtech industry together in order to create new partnerships and business opportunities



Medicon Valley Alliance Microbiome Network will increase opportunities for researchers from industry and academia to meet and collaborate



The Medicon Valley Alliance Executive Club is an exclusive network of executives representing life science and investor companies, science parks, higher learning institutions and regional councils

AGENDA

Moderator: Johan Malm, Professor Clinical Chemistry, Lund University

Welcome and Introduction

Petter Hartman, CEO, Medicon Valley Alliance

Johan Malm, Professor Clinical Chemistry, Lund University

The value of IP in personalised medicine

Jens Viktor Nørgaard, Partner, Head of Biotechnology & Plant Sciences, European Patent Attorney, Høiberg

European Cancer Moonshot Center Lund

György Marko Varga, Professor Clinical protein Science and Imaging, Lund University

Whole-genome sequencing, mutational signatures and interventions in cancer therapy

Eva Hoffmann, Professor Molecular Genetics, University of Copenhagen

Challenges in Cancer Pathology

Martin Johansson, Professor, Clinical Pathology, Lund University

Tissue diagnostics of the future

Krzysztof Krawczyk, Project Manager, Lumito AB

Scandion Oncology – Clinical Phase II biotechnology company targeting cancer drug resistance

Jan Stenvang, Chief Technology Officer, Scandion Oncology A/S

Public- private partnerships: a strong way forward to maximize impact

Erik Steinfelder, Biobanking Market Development Director, Thermo Fisher Scientific

Panel discussion: Potential areas for collaboration in Medicon Valley

Final remarks and conclusions

Johan Malm, Professor Clinical Chemistry, Lund University & Petter Hartman, CEO, Medicon Valley Alliance



MVA Oncology Network

Panel and Q&A: Potential areas of collaboration in Medicon Valley

In Collaboration with:



LUND UNIVERSITY



UNIVERSITY OF
COPENHAGEN

Sponsored by:

HØIBERG
European Patent Attorneys

**ONCOLOGY
NETWORK**
Medicon Valley Alliance



MVA Oncology Network

Thank you!

In Collaboration with:



LUND UNIVERSITY



UNIVERSITY OF
COPENHAGEN

Sponsored by:

HØIBERG
European Patent Attorneys

**ONCOLOGY
NETWORK**
Medicon Valley Alliance

